<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659386</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 08-4-010</org_study_id>
    <nct_id>NCT00659386</nct_id>
  </id_info>
  <brief_title>IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load</brief_title>
  <official_title>Intravenous Immunoglobulin Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Parvovirus B19 (PVB19) persistence in the heart has been associated with
      progressive cardiac dysfunction and evolution to dilated cardiomyopathy.

      Objective: Whether high dose of intravenous immunoglobulin (IVIg) in addition to conventional
      heart failure therapy achieves virus reduction, thereby resulting in improvement of cardiac
      function.

      Study design: A interventional study of virus presence and cardiac functional capacity before
      and after IVIg therapy.

      Study population: Patients with idiopathic cardiomyopathy and symptomatic heart failure for
      more than 1 year and a significant PVB19 viral load in endomyocardial biopsies (EMB) and
      treated with high dose of IVIg were included.

      Intervention (if applicable): Patients were treated with a total dose of 2 g/kg of immune
      globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 4 consecutive days.

      Main study parameters/endpoints: EMBs: virus (PVB19, enteroviruses, adenoviruses,
      Epstein-Barr virus, human herpes virus-6 and cytomegalovirus), inflammation (lymphocytes an
      macrophages) and fibrosis. Cardiac functional capacity: NYHA classification,
      echocardiographic evaluation (left ventricular ejection fraction, end-systolic diameter,
      end-diastolic diameter).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>viral loads in EMBs before and after therapy</measure>
    <time_frame>At baseline and 6 month follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic analysis, NYHA functional class, type/degree of inflammation and fibrosis in the myocardium.</measure>
    <time_frame>at baseline and at 6 month follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic idiopathic cardiomyopathy and EMB proven high PVB19 virus load.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin therapy</intervention_name>
    <description>Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>IVIG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic heart failure &lt;1 year.

          -  Optimal conventional heart failure medication &lt;6 months.

          -  PVB19 viral load &gt;150copies/mcg DNA in EMBs.

        Exclusion Criteria:

          -  significant (lesions &gt;50% stenosis) coronary artery disease.

          -  significant valvular disease.

          -  systemic diseases such as sarcoidosis, giant cell myocarditis, hemochromatosis, or
             systemic autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Heymans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert M Dennert, MD</last_name>
    <phone>+31433875102</phone>
    <email>robertdennert@cardio.azm.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Dennert</last_name>
      <email>robertdennert@cardio.azm.nl</email>
    </contact>
    <investigator>
      <last_name>Stephane Heymans, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>S. Heymans</name_title>
    <organization>Maastricht UMC+</organization>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Parvovirus B19</keyword>
  <keyword>Intravenous immuneglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

